Key result
Prolonged dual antiplatelet therapy duration (≥7 months) was not associated with a significant difference in overall cardiovascular events compared to 1-3 months, but increased major bleeding risk in patients with chronic kidney disease.
Why the study?
DAPT after PCI reduces thrombotic risk in ACS but may increase bleeding, especially in CKD, prompting evaluation of the impact of different DAPT durations in patients with and without CKD.
Does prolonged dual antiplatelet therapy duration reduce cardiovascular events or increase bleeding in patients with acute coronary syndrome post-percutaneous coronary intervention?
Cohort (n=4,800)
Does prolonged dual antiplatelet therapy duration reduce cardiovascular events or increase bleeding in patients with acute coronary syndrome post-percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
In ACS patients post-PCI, extending DAPT beyond 1-3 months did not significantly reduce 1-year cardiovascular events but significantly increased major bleeding risk in those with chronic kidney disease.
Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) reduces thrombotic risk in acute coronary syndrome (ACS) but may increase bleeding, especially in chronic kidney disease (CKD). This study evaluated the impact of different DAPT durations on cardiovascular and bleeding outcomes in ACS patients with and without CKD. Using the Taiwan National Health Insurance Research Database (2001-2018), patients ≥20 years with ACS who underwent PCI and received clopidogrel plus aspirin for ≥1 month were analyzed. Primary outcomes were cardiovascular events and bleeding events. Subgroup analysis was conducted by CKD status, which was defined using claims-based International Classification of Diseases, Ninth and Tenth Revision (ICD-9/ICD-10) diagnostic codes. Among 4,800 patients with ACS identified (median age: 62 years; 77% male), there were no significant differences in cardiovascular events across DAPT duration groups. No associations between DAPT duration and cardiovascular outcomes were identified in patients with or without CKD. However, DAPT duration ≥7 months was associated with a higher incidence of other major bleeding in patients with CKD (adjusted odds ratio [aOR] = 29.7, 95% confidence interval [CI]: 1.80-491.05,
No takes yet. Share an insight, caveat, or question.
Chang et al. (2026) conducted a cohort in Acute coronary syndrome post-percutaneous coronary intervention (n=4,800). Dual antiplatelet therapy duration ≥7 months vs. Dual antiplatelet therapy duration of 1-3 months was evaluated on Overall cardiovascular events (composite of AMI, ischemic stroke, TIA, or revascularization/fibrinolysis within 1 year) (aOR 0.76, 95% CI 0.45-1.27, p=0.293). Prolonged dual antiplatelet therapy duration (≥7 months) was not associated with a significant difference in overall cardiovascular events compared to 1-3 months, but increased major bleeding risk in patients with chronic kidney disease.
Synapse has enriched 10 related papers. Consider them for comparative context: